Autolus Therapeutics (NASDAQ:AUTL) Shares Gap Up – Time to Buy?

Autolus Therapeutics plc (NASDAQ:AUTL)’s stock price gapped up before the market opened on Monday . The stock had previously closed at $2.26, but opened at $2.34. Autolus Therapeutics shares last traded at $2.22, with a volume of 209,357 shares traded.

Analysts Set New Price Targets

A number of equities analysts have recently weighed in on AUTL shares. The Goldman Sachs Group upgraded Autolus Therapeutics from a “neutral” rating to a “buy” rating and increased their target price for the stock from $7.00 to $7.60 in a research note on Monday, November 18th. Redburn Atlantic raised Autolus Therapeutics from a “neutral” rating to a “buy” rating and set a $13.00 price objective on the stock in a report on Friday, November 15th. Finally, Needham & Company LLC reissued a “buy” rating and set a $10.00 target price on shares of Autolus Therapeutics in a report on Thursday, December 5th. Five research analysts have rated the stock with a buy rating, According to MarketBeat, Autolus Therapeutics presently has a consensus rating of “Buy” and an average target price of $10.40.

Autolus Therapeutics Stock Down 2.2 %

The firm has a 50 day moving average of $3.18 and a 200-day moving average of $3.71. The firm has a market capitalization of $588.07 million, a P/E ratio of -1.83 and a beta of 1.98.

Autolus Therapeutics (NASDAQ:AUTL) last issued its quarterly earnings results on Tuesday, November 12th. The company reported ($0.31) EPS for the quarter, missing analysts’ consensus estimates of ($0.21) by ($0.10). During the same period in the prior year, the company posted ($0.26) earnings per share. As a group, research analysts expect that Autolus Therapeutics plc will post -0.94 EPS for the current year.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the company. ProShare Advisors LLC bought a new position in shares of Autolus Therapeutics in the 2nd quarter valued at $43,000. Capstone Investment Advisors LLC acquired a new stake in Autolus Therapeutics in the third quarter valued at about $51,000. Daiwa Securities Group Inc. grew its position in Autolus Therapeutics by 2,659.7% in the second quarter. Daiwa Securities Group Inc. now owns 15,868 shares of the company’s stock valued at $55,000 after acquiring an additional 15,293 shares during the last quarter. Herbst Group LLC acquired a new position in Autolus Therapeutics during the third quarter worth about $91,000. Finally, China Universal Asset Management Co. Ltd. lifted its holdings in shares of Autolus Therapeutics by 63.8% in the third quarter. China Universal Asset Management Co. Ltd. now owns 38,393 shares of the company’s stock worth $139,000 after acquiring an additional 14,959 shares during the last quarter. 72.83% of the stock is currently owned by institutional investors and hedge funds.

About Autolus Therapeutics

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma.